Combined Serum CA125 And HE4 To Predict And Monitor Recurrence Of Type ? Endometrial Carcinoma

Purpose: To date,there was no internationally recognized serum biomarker to predict the recurrence of EC.The purpose of this study was to explore the serum serum human epididymis protein 4(HE4)and cancer antigen 125(CA125)for predicting recurrence of type II endometrial carcinoma and to identify the optimal cut-off value of biomarkers for type II endometrial carcinoma in recurrence.Methods: Women diagnosed with type II endometrial carcinoma at The First Affiliated Hospital of Chongqing Medical University between May 2011 and August 2019 were selected for this retrospective study.Serum HE4 and CA125 were collected at primary diagnosis,after the operation,during follow-up,at recurrence or at last follow-up.SPSS statistical software was used to analyze the data,ROC curve was drawn to select the cut-off value.Our study try to analysis the serological markers for monitoring the recurrence of type II endometrial carcinoma.Results: For 191 patients with type II endometrial carcinoma,comparing recurrent with non-recurrent patients,serum HE4 having a statistically significant difference between primary diagnosis and recurrence,respectively(P < 0.05),while serum CA125 just resulted statistically significant(P < 0.05)at recurrence.According to receiver operating characteristic(ROC)curve analysis,the areas under the curve(AUC)were significant for serum HE4 at primary diagnosis and recurrence,serum CA125 at recurrence.Furthermore,the AUC were significant for serum HE4 at primary diagnosis and recurrence,serum CA125 at recurrence.The sensitivity and specificity of pretreatmen serum HE4 in predicting the recurrence of type II endometrial carcinoma were 46.6% and83.9%,respectively.we found out that serum HE4 and serum CA125 were able to detection recurrence earlier during follow-up,with a sensitivity of60.7 %,67.9% and a specificity of 95.7 %,92.5%,respectively.The combination of both markers showed the higher sensitivity and specifity in comparison to serum HE4 alone,with a sensitivity and specificity(80.6%,91.5%,respectively)for recurrence.Conclusion: At present,there is no specific serological marker for endometrial carcinoma,and the accuracy of single serological marker is poor.Combined serum HE4 and CA125 will be easier to predict and monitor recurrence,serum HE4 and CA125 as the promising serum biomarker for type II endometrial carcinoma,which may be an excellent aid to predict and monitor recurrence of type II endometrial carcinoma.